Insights
Not AI news. Not vendor hype. Practical perspectives from working inside complex, compliance-driven workflows every day.
Hundreds of public comments on generative AI in medical devices suggest the FDA's approach will take time to settle. The correction rate on generated output is something device companies can start measuring now.
AI change management works best as a recurring cycle, and in a regulated company every lap of that cycle produces controlled changes. The simplest way to keep up is to run the AI review inside the management reviews, system reviews and controls testing you already have.
Predictive maintenance models will sometimes recommend deferring a scheduled service. In a regulated plant, that interval is a documented quality requirement, and changing it takes evidence and an approved procedure.
Most mid-market firms use generative AI, but few have it in core operations. In regulated companies, a written executive mandate with named owners and decision rights is what moves AI into controlled processes.
Adaptive AML and KYC tools change their own behavior over time. Before adopting one, compliance leaders should confirm they can show an examiner exactly why a customer was approved or an alert was cleared months earlier.
AI governance tools now come with tables mapping their features to the EU AI Act, NIST AI RMF and ISO/IEC 42001. Quality and compliance leaders should read those tables for what they leave to the organization, especially record-keeping and human oversight.
AI planning systems learn from past transactions, and a new tariff can make that history wrong overnight. Manufacturers can keep trade and site assumptions current by managing them as owned, versioned rules before planning runs with less human review.
AI workflows change far more often than the procedures that describe them. Regulated companies need an agreed way to decide which changes require an SOP revision and retraining, and a way to enforce it.
When an AI agent reads across complaint, service and CAPA systems, every piece of data it touches needs a named system of record. Device makers can start with a record ownership map built before any integration work begins.
Sombra's 2026 AI governance guide asks enterprises to document how each safeguard is enforced at runtime. For an AI workflow in a regulated company, that means stating where each control lives and what evidence it produces.
Every automated workflow depends on the systems it connects to. In regulated work, what the workflow does when one of those systems is unavailable needs to be designed and tested before go-live.
A new AI change management framework argues that a locally installed tool can spread across a company from a single executive's sign-off. In a regulated company, that path still needs a named owner for every regulated process the tool touches.
AI tools can now flag supply disruptions early and propose replacement suppliers. In regulated manufacturing, each of those proposals starts a qualification process, and the systems need to be built around that fact.
When a team redesigns a workflow around an AI agent, it decides what the agent may do on its own and what record it leaves behind, and those are compliance decisions. That work can be divided so that operations, IT, data and quality each own a defined part of it.
Abto Software's list of top AI automation firms shows entry prices ranging from $10,000+ to $100,000+. For regulated mid-market companies, that range is a reason to write the project scope, including approvals and audit trail requirements, before reading any ranking.
AI workforce plans usually end with retiring the manual process. In a regulated company, that step affects procedures, signature authority and your ability to keep working when the agent is down.
AI forecasting tools produce short-range and mid-range forecasts that cover the same weeks. Companies that plan production against them need a written rule for which number drives the order and who can override it.
Every major financial services firm has an AI roadmap for 2026. Most of them are sequenced wrong — and the order of operations will determine who actually deploys versus who spends another year in pilot purgatory.
Every AI change management framework assumes you have dedicated people to run it. Mid-market companies in regulated industries don't. Here's what to do instead.
Everyone in financial services is talking about enterprise-wide AI deployment in 2026. Almost nobody is talking about the operational infrastructure required to make it survivable.
Every AI workforce transformation guide tells you the same thing: 18 to 36 months to full deployment. What they don't tell you is that timeline assumes infrastructure, governance, and organizational capacity you probably haven't built.
The FDA's June 2026 draft guidance on AI-enabled medical devices isn't asking for better paperwork. It's asking whether your AI actually behaves the way you said it would — over time, in the real world.
Gartner and McKinsey say late AI adopters will lose ground. That's probably true. What they don't say is that 'adopting AI' and 'capturing productivity gains' are two completely different problems.
The FDA's updated AI/ML guidance isn't just a document for your regulatory affairs team to file. It's a stress test of whether your internal operations can actually support an AI-enabled product over its full lifecycle.
Every AI workforce strategy deck promises productivity gains and capability uplift. Most of them are describing a company that doesn't exist yet — and won't, without a different kind of plan.
Every 2026 AI manufacturing forecast promises autonomous production planning and self-optimizing supply chains. Here's what those forecasts don't mention: the operational conditions required before any of that works.
Everyone says AI helps mid-market companies compete with the big players. In regulated industries, that story skips a few chapters most operators can't afford to ignore.
Every 2026 AI guide for mid-sized companies assumes you can just start. In regulated industries, that assumption will cost you more than the software.
The 2026 benchmark data on AI automation ROI is solid — and heavily conditional. Here's what mid-market operators in regulated industries need to read between the lines.
The FDA's 2025 AI guidance isn't the hard part. What happens inside your quality system when AI touches every step of validation — that's where mid-market manufacturers are going to get stuck.
Everyone's talking about AI governance frameworks. Almost nobody has built one that actually runs in production. Here's the difference — and what mid-market companies need to do about it.
Every major vendor is pitching agentic AI for manufacturing. Most mid-market operators will buy it before they've fixed the data, process, and change management problems that killed the last wave of automation.
Everyone is scrambling to build AI inventories and model lifecycle policies. Almost nobody is asking whether their operations can actually enforce them.
95% of retailers report AI-driven cost reductions. That stat tells you what AI promised — not what it took to actually deliver it in a mid-market operation with real constraints.
Everyone's still asking 'is our AI working?' The better question is whether your organization is actually built to use it. Most aren't — and that gap is where ROI goes to die.
Enterprise AI spend is up. Value is not. The gap isn't the technology — it's what happens after the contract is signed.
Every 'top AI automation companies' list shows you who can build. None of them tell you what happens when the build is done and the real work begins.
A $100M bet on AI-native cloud infrastructure just exposed a gap that most mid-market operators in regulated industries haven't accounted for. Your AI workflow problem might not be the AI.
Getting ISO 13485 certified is the beginning of your compliance burden, not the end. Here's what mid-market medical device manufacturers need to build before AI can actually help.
The FDA's 2026 AI framework isn't a future concern — the PCCP guidance is already in effect for new submissions. Here's what that actually means for mid-market device manufacturers trying to ship AI-enabled products.
Stanford's new AI Playbook analyzed 51 real deployments. The top reasons they failed have nothing to do with the model — and everything to do with how your organization actually works.
Most distributors aren't losing margin because their forecasting model is bad. They're losing it because their bad forecast sits uncorrected for too long. That's a workflow problem, not a software problem.
Task-level AI wins are real. But if you're not seeing it in your operations, the problem isn't the AI — it's where you plugged it in.
Big banks going to production with AI tells you something important — but not what the headlines say. For mid-market financial services firms, the real question isn't whether AI works. It's whether your org can actually run it.
Every AI automation vendor claims production-ready. Most mean 'it worked in the demo.' Here's how to evaluate vendors the way a regulated industry actually needs to.
The bottleneck in most mid-market AI deployments isn't the model. It's the infrastructure underneath it — and the compliance overhead baked into every layer.
Everyone's excited about agentic AI in manufacturing. Almost no one has the data infrastructure to actually run it. Here's what mid-market operators need to understand before they commit.
The research is in: only 5% of enterprises see substantial AI returns. For mid-market operators in regulated industries, that number should be a wake-up call — not about AI itself, but about how you're deploying it.
Most regulated companies celebrate a successful AI pilot. They shouldn't. The pilot is where AI goes to die quietly — and the medical device industry is proof.
Every regulated industry is shopping for AI governance platforms in 2026. Most are buying tools before they've answered the harder question: who actually owns AI risk inside your organization?
Most AI adoption research treats "struggling" as a fixable technology problem. In regulated industries, it's a workflow design problem — and the fix looks completely different.
NVIDIA's 2026 State of AI report says companies are seeing real revenue gains and cost cuts from AI. Mid-market operators in regulated industries are largely watching from the sidelines. Here's why — and what to do about it.
Everyone is talking about AI on the manufacturing floor. Almost nobody is talking about what happens six months after go-live when the change control queue is full and the shift supervisor still doesn't trust the system.
Most manufacturers have a proof-of-concept that impressed someone in a conference room. Very few have AI that runs in production without a babysitter. Here's why — and what to do about it.
Enterprise AI automation platforms look impressive in demos. But most mid-market manufacturers don't have the infrastructure, the IT staff, or the change control process to survive implementation. Here's what to do instead.
Every mid-market operator knows AI matters. Almost none of them have figured out where to actually put it to work. Here's why the 'where to start' question is a distraction — and what to ask instead.
Boards and executives are being told to institutionalize AI governance as a core competency. For mid-market companies in regulated industries, that mandate is arriving before most of them have a working governance structure to build from.
Nearly every manufacturer is looking at AI. Almost none of them have the data infrastructure to run it. That's not an AI problem — it's an operations problem.
Every year a new ranked list of automation platforms drops, and every year mid-market operators in regulated industries buy the wrong thing for the wrong reasons. Here's what the rankings don't tell you.
Most mid-market companies in regulated industries have an AI policy now. Almost none of them have figured out how to actually run it. That gap is where the real compliance risk lives.
Regulated industries keep buying better AI models and still failing compliance reviews. The problem isn't the model — it's everything the model touches.
Everyone is adding AI tools to their workflow. Almost nobody is connecting them to a process that survives compliance review. Here's what that gap actually costs you.
The workflow automation market is booming. But the platforms driving that growth were designed for GTM teams at SaaS companies — not for ops managers at medical device firms trying to keep compliance teams happy.
Most financial services firms bolt compliance onto AI workflows as an afterthought. That's exactly why their implementations fail — and why the firms getting traction are building the opposite way.
Every retail and CPG company is chasing AI-driven demand forecasting and supply chain orchestration. Almost none of them are asking the right question first: who actually owns the decision the AI is informing?
Everyone's chasing AI transformation. The companies actually seeing returns are targeting something much smaller — the dead time between steps. Here's what that looks like in practice.
FDA's evolving AI/ML SaMD framework isn't a checklist you complete at launch. It's a continuous obligation — and most mid-market device companies aren't built for that.
Every 2026 survey shows retail and CPG leaders bullish on AI. The production reality is far messier — and mid-market operators are the ones absorbing the gap.
The FDA is being pushed to apply clinical laboratory validation standards to AI in medical devices. If you're building AI workflows in this space, that changes the math on what 'ready to deploy' actually means.
MIT research says 95% of enterprise AI projects don't deliver ROI. In regulated industries, the number feels even higher — and the reason isn't the technology.
Every workflow automation vendor is pitching AI-powered efficiency in 2026. Here's why picking the platform before solving the governance problem is how regulated-industry companies end up with a very expensive mess.
Everyone's talking about the 95% failure rate for enterprise AI. But for mid-market operators in regulated industries, the failure mode looks very different — and so does the fix.
Mid-market manufacturers keep buying enterprise AI tools and watching them stall at the integration layer. The problem isn't the algorithm — it's everything the algorithm has to talk to.
The medical device companies getting buried by FDA's evolving AI framework aren't failing on regulatory knowledge — they're failing because they bolted compliance onto a workflow that was never built to carry it.
Everyone in financial services is talking about converging their AI into one unified architecture. Most of them are about to make the same expensive mistake.
Most medical device companies are treating FDA's new AI requirements as a regulatory checkbox. That's exactly why they'll fail. Here's what the framework actually demands — and what it means for how you build.
Manufacturers are pouring money into AI pilots while their scheduling runs on spreadsheets and tribal knowledge. The use cases with the fastest payback aren't the flashy ones.
Everyone's automating invoice coding. Almost nobody is building the compliance scaffolding that makes it stick. Here's the gap mid-market CFOs keep falling into.
Everyone's talking about AI-driven inventory automation. Most mid-market operators are still running on spreadsheets and gut feel. Here's the gap — and how to close it without blowing up your ops.
The FDA's finalizing AI guidance that demands explainability, transparency, and real-world monitoring — and most mid-market device makers aren't remotely ready. Here's what that actually means for your workflows.
MIT found that 95% of enterprise AI pilots deliver zero measurable ROI. For companies in medical device, financial services, or manufacturing, the failure rate isn't just a budget problem — it's a compliance and operational risk.
Manufacturers are moving AI out of the pilot lab and into operations. That's the good news. The hard part — integration, compliance, and change control — is just getting started.
Mid-market manufacturers keep buying AI tools and getting marginal results. The problem isn't the tools — it's that nobody connected them to anything that matters.
Most financial services firms are building AI governance programs that look good on paper and collapse under operational weight. Here's what actually works.
FDA easing oversight on lower-risk AI devices sounds like good news. For mid-market manufacturers, it's actually a trap if you haven't built the right internal scaffolding first.
FDA and EU regulators are locking in AI oversight frameworks for 2026. Most mid-market medical device companies aren't close to ready — and the gap isn't technical, it's operational.
The FDA's 2025 draft guidance on AI-enabled devices buried a major compliance shift inside a document that doesn't even say 'human factors' in the title. Here's what it actually means for your validation strategy.
The FDA just drew clearer lines around AI in medical devices. For mid-market operators, this isn't a compliance headache — it's a forcing function that separates serious AI programs from expensive experiments.
New posts go out when they're ready — no filler, no cadence for cadence's sake.
Get in Touch